https://www.selleckchem.com/pr....oducts/d-luciferin.h
Objective Several guidelines recommend oral administration of nimodipine as vasospasm prophylaxis after aneurysmal subarachnoid hemorrhage (SAH). However, in clinical practice, the drug is administered orally and intravenously (i.v.), depending on clinical conditions and local treatment regimens. We have therefore investigated the safety and clinical effects of switching from i.v. to oral nimodipine therapy. Methods Patients with aneurysmal SAH between January 2014 and April 2018 and initial i.v. nimodipine therapy, which was subseq
Like
Comment
Share
